Three Diabetes Drug Classes, One Verdict: Meta-Analysis Confirms Kidney and Heart Protection
A new meta-analysis of 23 randomized trials finds that SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal mineralocorticoid receptor antagonists each ...
